| Drug Name |
Bicalutamide |
| Drug ID |
BADD_D00271 |
| Description |
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. |
| Indications and Usage |
For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer. |
| Marketing Status |
approved |
| ATC Code |
L02BB03 |
| DrugBank ID |
DB01128
|
| KEGG ID |
D00961
|
| MeSH ID |
C053541
|
| PubChem ID |
2375
|
| TTD Drug ID |
D0V9BD
|
| NDC Product Code |
49711-1504; 49711-1509; 51846-1028; 62559-890; 71205-577; 0904-6019; 53104-7664; 16714-816; 60429-177; 62559-680; 43265-7195; 46014-1111; 82920-004; 54893-0001; 16729-023; 58623-0068; 63629-8308; 15308-0360; 47335-485 |
| UNII |
A0Z3NAU9DP
|
| Synonyms |
bicalutamide | 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide | Casodex | Cosudex | ICI-176334 | ICI 176334 |
